The Africa anticancer drugs market size is projected to reach US$ 3.23 billion by 2031 from US$ 1.81 billion in 2024. The market is expected to register a CAGR of 8.8% during 2025–2031. Artificial intelligence accelerating cancer care is likely to be a key Africa anticancer drugs market trend.
Africa Anticancer Drugs Market Analysis
The increasing incidence of cancer and surging initiatives to improve cancer awareness are crucial factors driving the Africa anticancer drugs market. Burgeoning investments and government initiatives are further expected to contribute the market growth in the future. Moreover, the elevating number of clinical trials is expected to create ample opportunities for market growth during the forecast period.
Africa Anticancer Drugs Market Overview
Africa is gradually gaining prominence in the anticancer drugs market owing to the increasing prevalence of cancer and growing awareness about its treatment. Pharmaceutical manufacturers are heavily investing in the region to ensure the availability of anticancer drugs for better treatment options. South Africa is one of the most developed countries in the region, followed by Egypt. In 2020, Egypt reported approximately 150,578 new cancer cases, with breast, liver, and bladder cancers being the most prevalent disease conditions. Age-standardized incidence rate stood at 166.1 per 100,000 population, indicating a demand for effective oncology treatments. As per The Global Economy 2025, healthcare expenditure per capita was US$ 180 in 2021, reflecting the government's efforts to improve healthcare services.
As per Trading Economics 2025, pharmaceutical imports were valued at US$ 3.62 billion in 2023. As per the Global Risk Community 2025, the country faces drug shortages, particularly for essential medications, due to supply chain disruptions and economic constraints. Despite these challenges, as per the ArabFinance 2024, Egypt exported US$ 1 billion worth of pharmaceuticals in 2023, with a further target of exports worth US$ 1.5 billion in 2024.
Egypt’s oncology landscape is undergoing transformation, bolstered by a growing domestic pharmaceutical industry and a renewed focus on innovation. However, access to cutting-edge treatments such as immunotherapies remains uneven, often concentrated in urban centers. Addressing workforce imbalances, decentralizing cancer diagnostics, and fostering international research partnerships could serve as high-impact strategies. Egypt’s long-term success will depend on its ability to integrate these efforts into a scalable, sustainable cancer care model.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Africa Anticancer Drugs Market: Strategic Insights
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Africa Anticancer Drugs Market: Strategic Insights
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Africa Anticancer Drugs Market Drivers and Opportunities
Rising Cancer Incidence toFavor Market
Cancer has emerged as a major health challenge in Africa, with alarming statistics underscoring its impact. According to the article titled "Emerging Cancer Disease Burden in a Rural Sub-Saharan African Population," published in July 2024, Africa contributed ~5.7% (1,100,100) incidence and 7.2% (712,800) mortality rates to the global cancer burden in the year 2020. It is estimated that cancer will cause a mortality of about one million by 2030 in Africa. As per GLOBOCAN 2022 data, 1.18 million new cancer cases were reported in Africa in 2022, and cancer-related mortality reached 763,843 in the same year.
Countries such as Egypt, Nigeria, and South Africa are experiencing the highest incidence and mortality rates. For instance, according to the International Agency for Research on Cancer (IARC) latest global cancer database, Egypt faced an estimated burden of over 150,500 new cancer cases in 2022 and more than 95,000 cancer-related deaths in the same year. The GLOBOCAN 2022 estimates indicate that Nigeria recorded 127,763 new cancer cases in 2022. This surge in cancer cases is primarily attributed to risk factors such as urbanization, aging populations, and lifestyle changes.
Sub-Saharan Africa has the highest rates of cervical cancer in the world. As per the article "Why Southern and Eastern Africa Have the World's Highest Rates of Cervical Cancer," published in March 2023, more than 300,000 women die from cervical cancer globally, including the death of nearly 80,000 women in sub-Saharan Africa, highlighting an urgent need for effective cancer treatments. As cancer cases continue to rise across Africa, the region experiences a persistent need for both immediate and long-term treatment solutions; thus, the development and accessibility of anticancer drugs are essential for offering targeted and effective treatment options that cater to the unique healthcare needs of diverse populations in Africa. Thus, the rising number of cancer cases favors the growth of the Africa anticancer drugs market.
Surging Number of Clinical Trials
In Sub-Saharan Africa, the cancer survival rates – as measured by the cancer mortality to incidence ratio – are nearly half that in high-income countries, which indicates an urgent need for research to bridge this gap. A review published in ClinicalTrials.gov (a National Institutes of Health repository) on clinical trials found only 26 cancer-related interventional trials across Africa, of which 6 were conducted in countries with predominantly brown patients. However, the picture seems to be changing, and there are signs of progress. As per an article titled "The Kenyan Clinical Research Unit Bringing Precision Cancer Medicine to East Africa," published in May 2024, Roche, a Swiss pharmaceutical giant, runs 61 clinical trials in African countries, and two-thirds of these are focused on oncology. These trials span North African nations such as Morocco, Algeria, and Tunisia, and Sub-Saharan countries, including Ghana, Kenya, Nigeria, Uganda, and South Africa.
Expanding clinical trial capacities and investments have been key strategic goals of the African Organization for Research and Training in Cancer (AORTIC). As per an article titled "Landscape of Oncology Clinical Trials in Africa," published in July 2020, Egypt leads in terms of clinical trial activity among all African countries with 45 oncology trials, followed by South Africa with 11, and Algeria and Kenya hosting 10 each. North Africa was the densest region, with 63 clinical trials. These trials predominantly focus on breast, cervical, and lung cancers, indicating a targeted approach against cancer types that are prevalent in the region. Notably, academic institutions sponsor the majority of these trials, underscoring the importance of research-driven initiatives in advancing cancer treatment in Africa. The involvement of major pharmaceutical companies, including Hoffmann-La Roche, also underlines the mounting importance of the continent in the global cancer research landscape. Moreover, the establishment of the African Medicines Agency (AMA) aims to harmonize medical product regulations across the continent, enhancing the efficiency of clinical trials and facilitating the introduction of new anticancer drugs.
Initiatives such as Yemaachi Biotech's African Cancer Atlas and 54gene's efforts to enhance African genomic data representation are pivotal in the region's transformation into a cancer research destination. These projects aim to build comprehensive cancer databases, facilitating the development of targeted therapies tailored to African populations. Thus, an upsurge in the number of clinical trials in Africa presents significant opportunities for the further development of anticancer drugs.
Africa Anticancer Drugs Market Report Segmentation Analysis
Key segments that contributed to the derivation of the Africa anticancer drugs market analysis are drug class, indication, therapy type, dosage form, and sector.
- Based on drug class, the Africa anticancer drugs market is segmented into cytotoxic drugs, targeted drugs, hormonal drugs, immunotherapy drugs, gene therapy drugs, radiopharmaceuticals, and others. The cytotoxic drugs segment held the largest share in 2024. The targeted drugs segment is expected to register the highest CAGR during 2025–2031.
- Based on indication, the Africa anticancer drugs market is segmented into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, and others. The lung cancer segment held the largest market share in 2024, and the breast cancer segment is estimated to register the highest CAGR in the market during 2025–2031.
- In terms of therapy type, the Africa anticancer drugs market is categorized into chemotherapy, targeted therapy, immunotherapy, gene therapy, radiopharmaceutical therapy, and others. The chemotherapy segment held the largest market share in 2024, and the same segment is estimated to register the highest CAGR in the market during 2025–2031.
- Based on dosage form, the Africa anticancer drugs market is categorized into tablet and capsule, injectable, and liquid. The tablet and capsule segment held the largest market share in 2024, and the same segment is estimated to register the highest CAGR in the market during 2025–2031.
- By sector, the market is bifurcated into public and private. The public segment held a larger share of the market in 2024. The private segment is estimated to register a higher CAGR during 2025–2031.
Africa Anticancer Drugs Market Share Analysis by Region
The African anticancer drugs market is subsegmented into South Africa, Egypt, Algeria, Morocco, Tunisia, Nigeria, Kenya, Ethiopia, Ghana, Côte d'Ivoire, Senegal, Libya, and the Rest of Africa. Issues of affordability, access, and health system inequality shape the adoption of anticancer drugs in South Africa. As per the Cancer Alliance, only 7 out of 24 essential cancer medicines are available in the public sector, which serves 84% of the population, while 21 are accessible in the private sector, which serves just 16%. According to CANSA, 7 of the most expensive specialty drugs in the country are cancer-related, with lenalidomide costing R882,000 (US$ 48,158.5) per year locally versus less than R32,000 (US$ 1,747.25) in India. Discovery Health reports that five-year survival rates are better in the private sector, highlighting disparities in care. The Competition Commission notes that oncology drugs, though just 1% of the total pharmaceutical market, face disproportionately high pricing and access barriers.
As per the HSP News Service, L.L.C. 2025, the country allocates approximately 8.5% of its GDP to healthcare, with 84% of the population relying on the public sector and 16% accessing private care. In 2020, nearly 110,000 new cancer cases were diagnosed, and this number is projected to rise to 138,000 by 2030 and 175,000 by 2040. Leading cancer types include breast, prostate, colorectal, and cervical, with breast cancer being the most prevalent among women and prostate cancer among men. Currently, cancer treatment in South Africa encompasses chemotherapy, targeted therapies, and immunotherapies. However, access to these treatments is uneven in the region. In 2023, Discovery Health Medical Scheme paid over R3.2 billion (US$ 0.174 billion) for cancer treatments, marking a 19% increase from the previous year. However, only 17.1% of the population is covered by medical schemes, leaving individuals to face high out-of-pocket expenses. As per the Observatory of Economic Complexity, South Africa's pharmaceutical trade reveals a reliance on imports. In 2022, the country imported US$ 1.75 billion worth of packaged medicaments, primarily from India, Germany, and France, while exporting US$ 322 million worth of these commodities, mainly to neighboring countries such as Namibia and Zimbabwe. This trade imbalance underscores the domestic market's dependence on foreign-manufactured oncology drugs.
The high cost of innovative therapies limits affordability, especially in the public sector. Additionally, regulatory complexities can delay the introduction of new drugs. Geographic disparities exacerbate access issues, with rural areas often underserved due to a concentration of healthcare professionals in urban centers. As stated by the South African Medical Research Council and the Cancer Alliance, improving access to generics and biosimilars, updating patent laws, and enhancing procurement systems could reduce costs and improve equity. With collaborative public–private strategies and stronger health policy frameworks, South Africa has the potential to create a sustainable anticancer drug market in the years ahead.
Africa Anticancer Drugs Market Report Scope
Africa Anticancer Drugs Market News and Recent Developments
The Africa anticancer drugs market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the market are listed below:
- The Eisai Co., Ltd started fully-fledged operations in Africa through it Africa subsidiary, Eisai Pharmaceuticals Africa (Pty) Ltd to sell its products through local distribution partners, marketing anticancer drugs Halaven and Lenvima, and the antiepileptic drug Fycompa. (Source: Eisai Co., Ltd; Press Release; 2024)
- Kwality Pharmaceuticals Ltd. (KPL) has successfully received approval for its prominent oncology oral solid dosage (OSD) product, Tamoxifen 20 mg Tablet, in South Africa (SAHPRA) through a site transfer process. (Source: Kwality Pharmaceuticals Ltd., Press Release, 2024)
- Cipla Medpro signed a partnership agreement with mAbxience (a global biotechnology company) in March 2022. This move aims to provide essential oncology and respiratory-related biosimilars in South Africa. (Source: Cipla, Press Release, 2022)
Africa Anticancer Drugs Market Report Coverage and Deliverables
The “Africa Anticancer Drugs Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering the following areas:
- Africa anticancer drugs market size and forecast at regional and country levels for all the key market segments covered under the scope
- Africa anticancer drugs market trends as well as market dynamics such as drivers, restraints, and key opportunities
- Detailed PEST/Porter’s Five Forces and SWOT analysis
- Africa anticancer drugs market analysis covering key market trends, regional and country framework, major players, regulations, and recent market developments
- Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the Africa anticancer drugs market
- Detailed company profiles
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The anticancer drugs market majorly consists of the players such Amgen Inc, Gilead Sciences Inc, Novartis AG, F. Hoffmann-La Roche Ltd, BeiGene Ltd, Takeda Pharmaceutical Co Ltd, GSK Plc, Sanofi SA, Cipla Ltd, Johnson & Johnson, Aspen Holdings, Pfizer Inc, AstraZeneca Plc, Merck & Co Inc, and Daiichi Sankyo Co Ltd.
Based on drug class, the Africa anticancer drugs market is segmented into cytotoxic drugs, targeted drugs, hormonal drugs, immunotherapy drugs, gene therapy drugs, radiopharmaceuticals, and others. The cytotoxic drugs segment held the largest market share in 2024.
By indication, the market is segmented into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, and others. The lung cancer segment held the largest share of the market in 2024.
In terms of therapy type, the market is segmented into chemotherapy, targeted therapy, immunotherapy, gene therapy, radiopharmaceutical therapy, and others. The chemotherapy segment held the largest market share in 2024.
Anticancer drugs are the medications used for the treatment of different cancer by controlling the growth and spread of cancer cells in the body. They work by either killing cancer cells directly or preventing them from multiplying. Unlike regular cells, cancer cells divide uncontrollably and can spread to other parts of the body. Anticancer drugs target these abnormal cells while trying to minimize damage to normal cells. There are many types of anticancer drugs, each working in different ways to attack cancer. Some damage the cancer cells’ DNA, some block the nutrients they need, and others help the immune system fight cancer.
The South Africa has dominated the anticancer drugs market owing to affordability, access, and health system inequality shape the adoption of anticancer drugs in South Africa which is expected to fuel the Africa anticancer drugs market by 2031.
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Analyst Market Outlook
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:
4. African Anticancer Drugs Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Cancer Prevalence, By Country
4.4 Cancer Therapeutics: Pricing Analysis, 2024
4.5 Import-export Scenario in Africa
4.6 Ecosystem Analysis
4.6.1 List of Vendors in the Value Chain
5. African Anticancer Drugs Market – Key Market Dynamics
5.1 African Anticancer Drugs Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Rising Cancer Incidence
5.2.2 Increasing Initiatives to Improve Cancer Awareness
5.3 Market Restraints
5.3.1 Unaffordability and Limited Availability of Cancer Drugs
5.4 Market Opportunities
5.4.1 Surging Number of Clinical Trials
5.5 Future Trends
5.5.1 Artificial Intelligence Accelerating Cancer Care
5.6 Impact of Drivers and Restraints:
6. African Anticancer Drugs Market – Global Market Analysis
6.1 African Anticancer Drugs Market Revenue (US$ Million), 2021–2031
6.2 African Anticancer Drugs Market Forecast Analysis
7. African Anticancer Drugs Market Analysis – by Drug Class Type
7.1 Cytotoxic Drugs
7.1.1 Overview
7.1.2 Cytotoxic Drugs: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Targeted Drugs
7.2.1 Overview
7.2.2 Targeted Drugs: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Hormonal Drugs
7.3.1 Overview
7.3.2 Hormonal Drugs: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Immunotherapy Drugs
7.4.1 Overview
7.4.2 Immunotherapy Drugs: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
7.5 Gene Therapy Drugs
7.5.1 Overview
7.5.2 Gene Therapy Drugs: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
7.6 Radiopharmaceuticals
7.6.1 Overview
7.6.2 Radiopharmaceuticals: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
8. African Anticancer Drugs Market Analysis – by Indication
8.1 Lung Cancer
8.1.1 Overview
8.1.2 Lung Cancer: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
8.2 Stomach Cancer
8.2.1 Overview
8.2.2 Stomach Cancer: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
8.3 Colorectal Cancer
8.3.1 Overview
8.3.2 Colorectal Cancer: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
8.4 Breast Cancer
8.4.1 Overview
8.4.2 Breast Cancer: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
8.5 Prostrate Cancer
8.5.1 Overview
8.5.2 Prostrate Cancer: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
9. African Anticancer Drugs Market Analysis – by Dosage Form
9.1 Tablet and Capsule
9.1.1 Overview
9.1.2 Tablet and Capsule: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
9.2 Injectable
9.2.1 Overview
9.2.2 Injectable: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
9.3 Liquid
9.3.1 Overview
9.3.2 Liquid: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
10. African Anticancer Drugs Market Analysis – by Therapy
10.1 Chemotherapy
10.1.1 Overview
10.1.2 Chemotherapy: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
10.2 Targeted Therapy
10.2.1 Overview
10.2.2 Targeted Therapy: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
10.3 Immunotherapy
10.3.1 Overview
10.3.2 Immunotherapy: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
10.4 Gene Therapy
10.4.1 Overview
10.4.2 Gene Therapy: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
10.5 Radiopharmaceutical Therapy
10.5.1 Overview
10.5.2 Radiopharmaceutical Therapy: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
10.6 Others
10.6.1 Overview
10.6.2 Others: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11. African Anticancer Drugs Market Analysis – by Sector
11.1 Private
11.1.1 Overview
11.1.2 Private: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
11.2 Public
11.2.1 Overview
11.2.2 Public: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
12. African Anticancer Drugs Market – Geographical Analysis
12.1 Africa
12.1.1 African Anticancer Drugs Market Overview
12.1.2 African Anticancer Drugs Market – Revenue, 2021 - 2031 (US$ Million)
12.1.2.1 African Anticancer Drugs Market – Revenue and Forecast Analysis – by Drug Class Type
12.1.2.2 African Anticancer Drugs Market – Revenue and Forecast Analysis – by Cytotoxic Drugs
12.1.2.3 African Anticancer Drugs Market – Revenue and Forecast Analysis – by Targeted Drugs
12.1.2.4 African Anticancer Drugs Market – Revenue and Forecast Analysis – by Hormonal Drugs
12.1.2.5 African Anticancer Drugs Market – Revenue and Forecast Analysis – by Indication
12.1.2.6 African Anticancer Drugs Market – Revenue and Forecast Analysis – by Dosage Form
12.1.2.7 African Anticancer Drugs Market – Revenue and Forecast Analysis – by Therapy
12.1.2.8 African Anticancer Drugs Market – Revenue and Forecast Analysis – by Sector
12.1.3 African Anticancer Drugs Market – Revenue and Forecast Analysis – by Country
12.1.3.1 South Africa: African Anticancer Drugs Market – Revenue, 2021 - 2031 (US$ Million)
12.1.3.1.1 South Africa: African Anticancer Drugs Market Breakdown, by Drug Class Type
12.1.3.1.2 South Africa: African Anticancer Drugs Market Breakdown, by Cytotoxic Drugs
12.1.3.1.3 South Africa: African Anticancer Drugs Market Breakdown, by Targeted Drugs
12.1.3.1.4 South Africa: African Anticancer Drugs Market Breakdown, by Hormonal Drugs
12.1.3.1.5 South Africa: African Anticancer Drugs Market Breakdown, by Indication
12.1.3.1.6 South Africa: African Anticancer Drugs Market Breakdown, by Dosage Form
12.1.3.1.7 South Africa: African Anticancer Drugs Market Breakdown, by Therapy
12.1.3.1.8 South Africa: African Anticancer Drugs Market Breakdown, by Sector
12.1.3.2 Egypt: African Anticancer Drugs Market – Revenue, 2021 - 2031 (US$ Million)
12.1.3.2.1 Egypt: African Anticancer Drugs Market Breakdown, by Drug Class Type
12.1.3.2.2 Egypt: African Anticancer Drugs Market Breakdown, by Cytotoxic Drugs
12.1.3.2.3 Egypt: African Anticancer Drugs Market Breakdown, by Targeted Drugs
12.1.3.2.4 Egypt: African Anticancer Drugs Market Breakdown, by Hormonal Drugs
12.1.3.2.5 Egypt: African Anticancer Drugs Market Breakdown, by Indication
12.1.3.2.6 Egypt: African Anticancer Drugs Market Breakdown, by Dosage Form
12.1.3.2.7 Egypt: African Anticancer Drugs Market Breakdown, by Therapy
12.1.3.2.8 Egypt: African Anticancer Drugs Market Breakdown, by Sector
12.1.3.3 Algeria: African Anticancer Drugs Market – Revenue, 2021 - 2031 (US$ Million)
12.1.3.3.1 Algeria: African Anticancer Drugs Market Breakdown, by Drug Class Type
12.1.3.3.2 Algeria: African Anticancer Drugs Market Breakdown, by Cytotoxic Drugs
12.1.3.3.3 Algeria: African Anticancer Drugs Market Breakdown, by Targeted Drugs
12.1.3.3.4 Algeria: African Anticancer Drugs Market Breakdown, by Hormonal Drugs
12.1.3.3.5 Algeria: African Anticancer Drugs Market Breakdown, by Indication
12.1.3.3.6 Algeria: African Anticancer Drugs Market Breakdown, by Dosage Form
12.1.3.3.7 Algeria: African Anticancer Drugs Market Breakdown, by Therapy
12.1.3.3.8 Algeria: African Anticancer Drugs Market Breakdown, by Sector
12.1.3.4 Morocco: African Anticancer Drugs Market – Revenue, 2021 - 2031 (US$ Million)
12.1.3.4.1 Morocco: African Anticancer Drugs Market Breakdown, by Drug Class Type
12.1.3.4.2 Morocco: African Anticancer Drugs Market Breakdown, by Cytotoxic Drugs
12.1.3.4.3 Morocco: African Anticancer Drugs Market Breakdown, by Targeted Drugs
12.1.3.4.4 Morocco: African Anticancer Drugs Market Breakdown, by Hormonal Drugs
12.1.3.4.5 Morocco: African Anticancer Drugs Market Breakdown, by Indication
12.1.3.4.6 Morocco: African Anticancer Drugs Market Breakdown, by Dosage Form
12.1.3.4.7 Morocco: African Anticancer Drugs Market Breakdown, by Therapy
12.1.3.4.8 Morocco: African Anticancer Drugs Market Breakdown, by Sector
12.1.3.5 Tunisia: African Anticancer Drugs Market – Revenue, 2021 - 2031 (US$ Million)
12.1.3.5.1 Tunisia: African Anticancer Drugs Market Breakdown, by Drug Class Type
12.1.3.5.2 Tunisia: African Anticancer Drugs Market Breakdown, by Cytotoxic Drugs
12.1.3.5.3 Tunisia: African Anticancer Drugs Market Breakdown, by Targeted Drugs
12.1.3.5.4 Tunisia: African Anticancer Drugs Market Breakdown, by Hormonal Drugs
12.1.3.5.5 Tunisia: African Anticancer Drugs Market Breakdown, by Indication
12.1.3.5.6 Tunisia: African Anticancer Drugs Market Breakdown, by Dosage Form
12.1.3.5.7 Tunisia: African Anticancer Drugs Market Breakdown, by Therapy
12.1.3.5.8 Tunisia: African Anticancer Drugs Market Breakdown, by Sector
12.1.3.6 Nigeria: African Anticancer Drugs Market – Revenue, 2021 - 2031 (US$ Million)
12.1.3.6.1 Nigeria: African Anticancer Drugs Market Breakdown, by Drug Class Type
12.1.3.6.2 Nigeria: African Anticancer Drugs Market Breakdown, by Cytotoxic Drugs
12.1.3.6.3 Nigeria: African Anticancer Drugs Market Breakdown, by Targeted Drugs
12.1.3.6.4 Nigeria: African Anticancer Drugs Market Breakdown, by Hormonal Drugs
12.1.3.6.5 Nigeria: African Anticancer Drugs Market Breakdown, by Indication
12.1.3.6.6 Nigeria: African Anticancer Drugs Market Breakdown, by Dosage Form
12.1.3.6.7 Nigeria: African Anticancer Drugs Market Breakdown, by Therapy
12.1.3.6.8 Nigeria: African Anticancer Drugs Market Breakdown, by Sector
12.1.3.7 Kenya: African Anticancer Drugs Market – Revenue, 2021 - 2031 (US$ Million)
12.1.3.7.1 Kenya: African Anticancer Drugs Market Breakdown, by Drug Class Type
12.1.3.7.2 Kenya: African Anticancer Drugs Market Breakdown, by Cytotoxic Drugs
12.1.3.7.3 Kenya: African Anticancer Drugs Market Breakdown, by Targeted Drugs
12.1.3.7.4 Kenya: African Anticancer Drugs Market Breakdown, by Hormonal Drugs
12.1.3.7.5 Kenya: African Anticancer Drugs Market Breakdown, by Indication
12.1.3.7.6 Kenya: African Anticancer Drugs Market Breakdown, by Dosage Form
12.1.3.7.7 Kenya: African Anticancer Drugs Market Breakdown, by Therapy
12.1.3.7.8 Kenya: African Anticancer Drugs Market Breakdown, by Sector
12.1.3.8 Ethiopia: African Anticancer Drugs Market – Revenue, 2021 - 2031 (US$ Million)
12.1.3.8.1 Ethiopia: African Anticancer Drugs Market Breakdown, by Drug Class Type
12.1.3.8.2 Ethiopia: African Anticancer Drugs Market Breakdown, by Cytotoxic Drugs
12.1.3.8.3 Ethiopia: African Anticancer Drugs Market Breakdown, by Targeted Drugs
12.1.3.8.4 Ethiopia: African Anticancer Drugs Market Breakdown, by Hormonal Drugs
12.1.3.8.5 Ethiopia: African Anticancer Drugs Market Breakdown, by Indication
12.1.3.8.6 Ethiopia: African Anticancer Drugs Market Breakdown, by Dosage Form
12.1.3.8.7 Ethiopia: African Anticancer Drugs Market Breakdown, by Therapy
12.1.3.8.8 Ethiopia: African Anticancer Drugs Market Breakdown, by Sector
12.1.3.9 Ghana: African Anticancer Drugs Market – Revenue, 2021 - 2031 (US$ Million)
12.1.3.9.1 Ghana: African Anticancer Drugs Market Breakdown, by Drug Class Type
12.1.3.9.2 Ghana: African Anticancer Drugs Market Breakdown, by Cytotoxic Drugs
12.1.3.9.3 Ghana: African Anticancer Drugs Market Breakdown, by Targeted Drugs
12.1.3.9.4 Ghana: African Anticancer Drugs Market Breakdown, by Hormonal Drugs
12.1.3.9.5 Ghana: African Anticancer Drugs Market Breakdown, by Indication
12.1.3.9.6 Ghana: African Anticancer Drugs Market Breakdown, by Dosage Form
12.1.3.9.7 Ghana: African Anticancer Drugs Market Breakdown, by Therapy
12.1.3.9.8 Ghana: African Anticancer Drugs Market Breakdown, by Sector
12.1.3.10 Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market – Revenue, 2021 - 2031 (US$ Million)
12.1.3.10.1 Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market Breakdown, by Drug Class Type
12.1.3.10.2 Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market Breakdown, by Cytotoxic Drugs
12.1.3.10.3 Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market Breakdown, by Targeted Drugs
12.1.3.10.4 Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market Breakdown, by Hormonal Drugs
12.1.3.10.5 Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market Breakdown, by Indication
12.1.3.10.6 Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market Breakdown, by Dosage Form
12.1.3.10.7 Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market Breakdown, by Therapy
12.1.3.10.8 Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market Breakdown, by Sector
12.1.3.11 Senegal: African Anticancer Drugs Market – Revenue, 2021 - 2031 (US$ Million)
12.1.3.11.1 Senegal: African Anticancer Drugs Market Breakdown, by Drug Class Type
12.1.3.11.2 Senegal: African Anticancer Drugs Market Breakdown, by Cytotoxic Drugs
12.1.3.11.3 Senegal: African Anticancer Drugs Market Breakdown, by Targeted Drugs
12.1.3.11.4 Senegal: African Anticancer Drugs Market Breakdown, by Hormonal Drugs
12.1.3.11.5 Senegal: African Anticancer Drugs Market Breakdown, by Indication
12.1.3.11.6 Senegal: African Anticancer Drugs Market Breakdown, by Dosage Form
12.1.3.11.7 Senegal: African Anticancer Drugs Market Breakdown, by Therapy
12.1.3.11.8 Senegal: African Anticancer Drugs Market Breakdown, by Sector
12.1.3.12 Libya: African Anticancer Drugs Market – Revenue, 2021 - 2031 (US$ Million)
12.1.3.12.1 Libya: African Anticancer Drugs Market Breakdown, by Drug Class Type
12.1.3.12.2 Libya: African Anticancer Drugs Market Breakdown, by Cytotoxic Drugs
12.1.3.12.3 Libya: African Anticancer Drugs Market Breakdown, by Targeted Drugs
12.1.3.12.4 Libya: African Anticancer Drugs Market Breakdown, by Hormonal Drugs
12.1.3.12.5 Libya: African Anticancer Drugs Market Breakdown, by Indication
12.1.3.12.6 Libya: African Anticancer Drugs Market Breakdown, by Dosage Form
12.1.3.12.7 Libya: African Anticancer Drugs Market Breakdown, by Therapy
12.1.3.12.8 Libya: African Anticancer Drugs Market Breakdown, by Sector
12.1.3.13 Rest of Africa: African Anticancer Drugs Market – Revenue, 2021 - 2031 (US$ Million)
12.1.3.13.1 Rest of Africa: African Anticancer Drugs Market Breakdown, by Drug Class Type
12.1.3.13.2 Rest of Africa: African Anticancer Drugs Market Breakdown, by Cytotoxic Drugs
12.1.3.13.3 Rest of Africa: African Anticancer Drugs Market Breakdown, by Targeted Drugs
12.1.3.13.4 Rest of Africa: African Anticancer Drugs Market Breakdown, by Hormonal Drugs
12.1.3.13.5 Rest of Africa: African Anticancer Drugs Market Breakdown, by Indication
12.1.3.13.6 Rest of Africa: African Anticancer Drugs Market Breakdown, by Dosage Form
12.1.3.13.7 Rest of Africa: African Anticancer Drugs Market Breakdown, by Therapy
12.1.3.13.8 Rest of Africa: African Anticancer Drugs Market Breakdown, by Sector
13. Competitive Landscape
13.1 Heat Map Analysis by Key Players
13.2 Company Positioning and Concentration
14. Industry Landscape
14.1 Overview
14.2 Market Initiative
14.3 Partnerships and Collaborations
14.4 Other Developments
15. Company Profiles
15.1 Amgen Inc
15.1.1 Key Facts
15.1.2 Business Description
15.1.3 Products and Services
15.1.4 Financial Overview
15.1.5 SWOT Analysis
15.1.6 Key Developments
15.2 Gilead Sciences Inc
15.2.1 Key Facts
15.2.2 Business Description
15.2.3 Products and Services
15.2.4 Financial Overview
15.2.5 SWOT Analysis
15.2.6 Key Developments
15.3 Novartis AG
15.3.1 Key Facts
15.3.2 Business Description
15.3.3 Products and Services
15.3.4 Financial Overview
15.3.5 SWOT Analysis
15.3.6 Key Developments
15.4 F. Hoffmann-La Roche Ltd
15.4.1 Key Facts
15.4.2 Business Description
15.4.3 Products and Services
15.4.4 Financial Overview
15.4.5 SWOT Analysis
15.4.6 Key Developments
15.5 BeiGene Ltd
15.5.1 Key Facts
15.5.2 Business Description
15.5.3 Products and Services
15.5.4 Financial Overview
15.5.5 SWOT Analysis
15.5.6 Key Developments
15.6 Takeda Pharmaceutical Co Ltd
15.6.1 Key Facts
15.6.2 Business Description
15.6.3 Products and Services
15.6.4 Financial Overview
15.6.5 SWOT Analysis
15.6.6 Key Developments
15.7 GSK Plc
15.7.1 Key Facts
15.7.2 Business Description
15.7.3 Products and Services
15.7.4 Financial Overview
15.7.5 SWOT Analysis
15.7.6 Key Developments
15.8 Sanofi SA
15.8.1 Key Facts
15.8.2 Business Description
15.8.3 Products and Services
15.8.4 Financial Overview
15.8.5 SWOT Analysis
15.8.6 Key Developments
15.9 Cipla Ltd
15.9.1 Key Facts
15.9.2 Business Description
15.9.3 Products and Services
15.9.4 Financial Overview
15.9.5 SWOT Analysis
15.9.6 Key Developments
15.10 Johnson & Johnson
15.10.1 Key Facts
15.10.2 Business Description
15.10.3 Products and Services
15.10.4 Financial Overview
15.10.5 SWOT Analysis
15.10.6 Key Developments
15.11 Aspen Holdings
15.11.1 Key Facts
15.11.2 Business Description
15.11.3 Products and Services
15.11.4 Financial Overview
15.11.5 SWOT Analysis
15.11.6 Key Developments
15.12 Pfizer Inc
15.12.1 Key Facts
15.12.2 Business Description
15.12.3 Products and Services
15.12.4 Financial Overview
15.12.5 SWOT Analysis
15.12.6 Key Developments
15.13 AstraZeneca Plc
15.13.1 Key Facts
15.13.2 Business Description
15.13.3 Products and Services
15.13.4 Financial Overview
15.13.5 SWOT Analysis
15.13.6 Key Developments
15.14 Merck & Co Inc
15.14.1 Key Facts
15.14.2 Business Description
15.14.3 Products and Services
15.14.4 Financial Overview
15.14.5 SWOT Analysis
15.14.6 Key Developments
15.15 Daiichi Sankyo Co Ltd
15.15.1 Key Facts
15.15.2 Business Description
15.15.3 Products and Services
15.15.4 Financial Overview
15.15.5 SWOT Analysis
16. Appendix
16.1 About The Insight Partners
16.2 Glossary of Terms
List of Tables
Table 1. African Anticancer Drugs Market Segmentation
Table 2. Methodology 1 – Africa Market
Table 3. Methodology 2 – Africa Market
Table 4. Each country’s market share is determined using five weighted parameters:
Table 5. Market Issues in African Anti-Cancer Drugs Market
Table 6. Cancer Prevalence, By Country- 2023
Table 7. Cancer Therapeutics, Pricing Analysis (Price (US$/Unit)- 2023
Table 8. Import Value and Quantity of Medicinal Products by Key African Countries (2024)
Table 9. Export Value and Quantity of Medicinal Products by Key African Countries (2024)
Table 10. List of Vendors
Table 11. African Anticancer Drugs Market – Revenue, 2021 - 2024 (US$ Million)
Table 12. African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million)
Table 13. Cytotoxic Drugs: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Table 14. Cytotoxic Drugs: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Table 15. Targeted Drugs: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Table 16. Targeted Drugs: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Table 17. Hormonal Drugs: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Table 18. Hormonal Drugs: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Table 19. African Anticancer Drugs Market – Revenue, 2021 - 2024 (US$ Million) – by Drug Class Type
Table 20. African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Drug Class Type
Table 21. African Anticancer Drugs Market – Revenue, 2021 - 2024 (US$ Million) – by Cytotoxic Drugs
Table 22. African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Cytotoxic Drugs
Table 23. African Anticancer Drugs Market – Revenue, 2021 - 2024 (US$ Million) – by Targeted Drugs
Table 24. African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Targeted Drugs
Table 25. African Anticancer Drugs Market – Revenue, 2021 - 2024 (US$ Million) – by Hormonal Drugs
Table 26. African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Hormonal Drugs
Table 27. African Anticancer Drugs Market – Revenue, 2021 - 2024 (US$ Million) – by Indication
Table 28. African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Indication
Table 29. African Anticancer Drugs Market – Revenue, 2021 - 2024 (US$ Million) – by Dosage Form
Table 30. African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Dosage Form
Table 31. African Anticancer Drugs Market – Revenue, 2021 - 2024 (US$ Million) – by Therapy
Table 32. African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Therapy
Table 33. African Anticancer Drugs Market – Revenue, 2021 - 2024 (US$ Million) – by Sector
Table 34. African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Sector
Table 35. South Africa: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Drug Class Type
Table 36. South Africa: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Drug Class Type
Table 37. South Africa: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Cytotoxic Drugs
Table 38. South Africa: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Cytotoxic Drugs
Table 39. South Africa: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Targeted Drugs
Table 40. South Africa: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Targeted Drugs
Table 41. South Africa: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Hormonal Drugs
Table 42. South Africa: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Hormonal Drugs
Table 43. South Africa: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Indication
Table 44. South Africa: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Indication
Table 45. South Africa: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Dosage Form
Table 46. South Africa: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Dosage Form
Table 47. South Africa: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Therapy
Table 48. South Africa: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Therapy
Table 49. South Africa: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Sector
Table 50. South Africa: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Sector
Table 51. Egypt: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Drug Class Type
Table 52. Egypt: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Drug Class Type
Table 53. Egypt: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Cytotoxic Drugs
Table 54. Egypt: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Cytotoxic Drugs
Table 55. Egypt: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Targeted Drugs
Table 56. Egypt: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Targeted Drugs
Table 57. Egypt: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Hormonal Drugs
Table 58. Egypt: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Hormonal Drugs
Table 59. Egypt: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Indication
Table 60. Egypt: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Indication
Table 61. Egypt: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Dosage Form
Table 62. Egypt: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Dosage Form
Table 63. Egypt: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Therapy
Table 64. Egypt: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Therapy
Table 65. Egypt: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Sector
Table 66. Egypt: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Sector
Table 67. Algeria: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Drug Class Type
Table 68. Algeria: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Drug Class Type
Table 69. Algeria: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Cytotoxic Drugs
Table 70. Algeria: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Cytotoxic Drugs
Table 71. Algeria: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Targeted Drugs
Table 72. Algeria: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Targeted Drugs
Table 73. Algeria: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Hormonal Drugs
Table 74. Algeria: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Hormonal Drugs
Table 75. Algeria: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Indication
Table 76. Algeria: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Indication
Table 77. Algeria: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Dosage Form
Table 78. Algeria: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Dosage Form
Table 79. Algeria: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Therapy
Table 80. Algeria: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Therapy
Table 81. Algeria: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Sector
Table 82. Algeria: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Sector
Table 83. Morocco: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Drug Class Type
Table 84. Morocco: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Drug Class Type
Table 85. Morocco: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Cytotoxic Drugs
Table 86. Morocco: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Cytotoxic Drugs
Table 87. Morocco: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Targeted Drugs
Table 88. Morocco: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Targeted Drugs
Table 89. Morocco: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Hormonal Drugs
Table 90. Morocco: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Hormonal Drugs
Table 91. Morocco: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Indication
Table 92. Morocco: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Indication
Table 93. Morocco: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Dosage Form
Table 94. Morocco: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Dosage Form
Table 95. Morocco: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Therapy
Table 96. Morocco: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Therapy
Table 97. Morocco: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Sector
Table 98. Morocco: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Sector
Table 99. Tunisia: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Drug Class Type
Table 100. Tunisia: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Drug Class Type
Table 101. Tunisia: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Cytotoxic Drugs
Table 102. Tunisia: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Cytotoxic Drugs
Table 103. Tunisia: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Targeted Drugs
Table 104. Tunisia: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Targeted Drugs
Table 105. Tunisia: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Hormonal Drugs
Table 106. Tunisia: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Hormonal Drugs
Table 107. Tunisia: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Indication
Table 108. Tunisia: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Indication
Table 109. Tunisia: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Dosage Form
Table 110. Tunisia: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Dosage Form
Table 111. Tunisia: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Therapy
Table 112. Tunisia: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Therapy
Table 113. Tunisia: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Sector
Table 114. Tunisia: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Sector
Table 115. Nigeria: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Drug Class Type
Table 116. Nigeria: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Drug Class Type
Table 117. Nigeria: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Cytotoxic Drugs
Table 118. Nigeria: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Cytotoxic Drugs
Table 119. Nigeria: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Targeted Drugs
Table 120. Nigeria: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Targeted Drugs
Table 121. Nigeria: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Hormonal Drugs
Table 122. Nigeria: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Hormonal Drugs
Table 123. Nigeria: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Indication
Table 124. Nigeria: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Indication
Table 125. Nigeria: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Dosage Form
Table 126. Nigeria: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Dosage Form
Table 127. Nigeria: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Therapy
Table 128. Nigeria: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Therapy
Table 129. Nigeria: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Sector
Table 130. Nigeria: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Sector
Table 131. Kenya: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Drug Class Type
Table 132. Kenya: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Drug Class Type
Table 133. Kenya: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Cytotoxic Drugs
Table 134. Kenya: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Cytotoxic Drugs
Table 135. Kenya: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Targeted Drugs
Table 136. Kenya: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Targeted Drugs
Table 137. Kenya: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Hormonal Drugs
Table 138. Kenya: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Hormonal Drugs
Table 139. Kenya: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Indication
Table 140. Kenya: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Indication
Table 141. Kenya: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Dosage Form
Table 142. Kenya: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Dosage Form
Table 143. Kenya: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Therapy
Table 144. Kenya: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Therapy
Table 145. Kenya: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Sector
Table 146. Kenya: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Sector
Table 147. Ethiopia: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Drug Class Type
Table 148. Ethiopia: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Drug Class Type
Table 149. Ethiopia: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Cytotoxic Drugs
Table 150. Ethiopia: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Cytotoxic Drugs
Table 151. Ethiopia: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Targeted Drugs
Table 152. Ethiopia: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Targeted Drugs
Table 153. Ethiopia: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Hormonal Drugs
Table 154. Ethiopia: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Hormonal Drugs
Table 155. Ethiopia: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Indication
Table 156. Ethiopia: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Indication
Table 157. Ethiopia: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Dosage Form
Table 158. Ethiopia: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Dosage Form
Table 159. Ethiopia: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Therapy
Table 160. Ethiopia: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Therapy
Table 161. Ethiopia: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Sector
Table 162. Ethiopia: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Sector
Table 163. Ghana: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Drug Class Type
Table 164. Ghana: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Drug Class Type
Table 165. Ghana: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Cytotoxic Drugs
Table 166. Ghana: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Cytotoxic Drugs
Table 167. Ghana: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Targeted Drugs
Table 168. Ghana: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Targeted Drugs
Table 169. Ghana: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Hormonal Drugs
Table 170. Ghana: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Hormonal Drugs
Table 171. Ghana: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Indication
Table 172. Ghana: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Indication
Table 173. Ghana: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Dosage Form
Table 174. Ghana: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Dosage Form
Table 175. Ghana: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Therapy
Table 176. Ghana: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Therapy
Table 177. Ghana: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Sector
Table 178. Ghana: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Sector
Table 179. Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Drug Class Type
Table 180. Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Drug Class Type
Table 181. Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Cytotoxic Drugs
Table 182. Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Cytotoxic Drugs
Table 183. Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Targeted Drugs
Table 184. Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Targeted Drugs
Table 185. Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Hormonal Drugs
Table 186. Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Hormonal Drugs
Table 187. Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Indication
Table 188. Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Indication
Table 189. Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Dosage Form
Table 190. Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Dosage Form
Table 191. Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Therapy
Table 192. Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Therapy
Table 193. Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Sector
Table 194. Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Sector
Table 195. Senegal: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Drug Class Type
Table 196. Senegal: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Drug Class Type
Table 197. Senegal: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Cytotoxic Drugs
Table 198. Senegal: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Cytotoxic Drugs
Table 199. Senegal: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Targeted Drugs
Table 200. Senegal: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Targeted Drugs
Table 201. Senegal: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Hormonal Drugs
Table 202. Senegal: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Hormonal Drugs
Table 203. Senegal: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Indication
Table 204. Senegal: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Indication
Table 205. Senegal: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Dosage Form
Table 206. Senegal: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Dosage Form
Table 207. Senegal: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Therapy
Table 208. Senegal: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Therapy
Table 209. Senegal: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Sector
Table 210. Senegal: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Sector
Table 211. Libya: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Drug Class Type
Table 212. Libya: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Drug Class Type
Table 213. Libya: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Cytotoxic Drugs
Table 214. Libya: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Cytotoxic Drugs
Table 215. Libya: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Targeted Drugs
Table 216. Libya: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Targeted Drugs
Table 217. Libya: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Hormonal Drugs
Table 218. Libya: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Hormonal Drugs
Table 219. Libya: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Indication
Table 220. Libya: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Indication
Table 221. Libya: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Dosage Form
Table 222. Libya: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Dosage Form
Table 223. Libya: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Therapy
Table 224. Libya: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Therapy
Table 225. Libya: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Sector
Table 226. Libya: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Sector
Table 227. Rest of Africa: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Drug Class Type
Table 228. Rest of Africa: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Drug Class Type
Table 229. Rest of Africa: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Cytotoxic Drugs
Table 230. Rest of Africa: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Cytotoxic Drugs
Table 231. Rest of Africa: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Targeted Drugs
Table 232. Rest of Africa: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Targeted Drugs
Table 233. Rest of Africa: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Hormonal Drugs
Table 234. Rest of Africa: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Hormonal Drugs
Table 235. Rest of Africa: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Indication
Table 236. Rest of Africa: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Indication
Table 237. Rest of Africa: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Dosage Form
Table 238. Rest of Africa: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Dosage Form
Table 239. Rest of Africa: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Therapy
Table 240. Rest of Africa: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Therapy
Table 241. Rest of Africa: African Anticancer Drugs Market – Revenue, 2021 - 2024(US$ Million) – by Sector
Table 242. Rest of Africa: African Anticancer Drugs Market – Revenue, 2025 - 2031 (US$ Million) – by Sector
Table 243. Glossary of Terms, African Anticancer Drugs Market
List of Figures
Figure 1. African Anticancer Drugs Market Segmentation, by Geography
Figure 2. PEST Analysis
Figure 3. Ecosystem Analysis
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. African Anticancer Drugs Market Revenue (US$ Million), 2021–2031
Figure 6. African Anticancer Drugs Market Share (%) – by Drug Class Type (2024 and 2031)
Figure 7. Cytotoxic Drugs: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 8. Targeted Drugs: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 9. Hormonal Drugs: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 10. Immunotherapy Drugs: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 11. Gene Therapy Drugs: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 12. Radiopharmaceuticals: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 13. Others: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 14. African Anticancer Drugs Market Share (%) – by Indication (2024 and 2031)
Figure 15. Lung Cancer: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 16. Stomach Cancer: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 17. Colorectal Cancer: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 18. Breast Cancer: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 19. Prostrate Cancer: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 20. Others: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 21. African Anticancer Drugs Market Share (%) – by Dosage Form (2024 and 2031)
Figure 22. Tablet and Capsule: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 23. Injectable: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 24. Liquid: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 25. African Anticancer Drugs Market Share (%) – by Therapy (2024 and 2031)
Figure 26. Chemotherapy: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 27. Targeted Therapy: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 28. Immunotherapy: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 29. Gene Therapy: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 30. Radiopharmaceutical Therapy: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 31. Others: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 32. African Anticancer Drugs Market Share (%) – by Sector (2024 and 2031)
Figure 33. Private: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 34. Public: African Anticancer Drugs Market – Revenue and Forecast to 2031 (US$ Million)
Figure 35. African Anticancer Drugs Market – Revenue, 2021 - 2031 (US$ Million)
Figure 36. African Anticancer Drugs Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 37. South Africa: African Anticancer Drugs Market – Revenue, 2021 - 2031 (US$ Million)
Figure 38. Egypt: African Anticancer Drugs Market – Revenue, 2021 - 2031 (US$ Million)
Figure 39. Algeria: African Anticancer Drugs Market – Revenue, 2021 - 2031 (US$ Million)
Figure 40. Morocco: African Anticancer Drugs Market – Revenue, 2021 - 2031 (US$ Million)
Figure 41. Tunisia: African Anticancer Drugs Market – Revenue, 2021 - 2031 (US$ Million)
Figure 42. Nigeria: African Anticancer Drugs Market – Revenue, 2021 - 2031 (US$ Million)
Figure 43. Kenya: African Anticancer Drugs Market – Revenue, 2021 - 2031 (US$ Million)
Figure 44. Ethiopia: African Anticancer Drugs Market – Revenue, 2021 - 2031 (US$ Million)
Figure 45. Ghana: African Anticancer Drugs Market – Revenue, 2021 - 2031 (US$ Million)
Figure 46. Cote d Ivoire (Ivory Coast): African Anticancer Drugs Market – Revenue, 2021 - 2031 (US$ Million)
Figure 47. Senegal: African Anticancer Drugs Market – Revenue, 2021 - 2031 (US$ Million)
Figure 48. Libya: African Anticancer Drugs Market – Revenue, 2021 - 2031 (US$ Million)
Figure 49. Rest of Africa: African Anticancer Drugs Market – Revenue, 2021 - 2031 (US$ Million)
Figure 50. Heat Map Analysis by Key Players
Figure 51. Company Positioning and Concentration
The List of Companies - Africa Anticancer Drugs Market
- Amgen Inc
- Gilead Sciences Inc
- Novartis AG
- F. Hoffmann-La Roche Ltd
- BeiGene Ltd
- Takeda Pharmaceutical Co Ltd
- GSK Plc
- Sanofi SA
- Cipla Ltd
- Johnson & Johnson
- Aspen Holdings
- Pfizer Inc
- AstraZeneca Plc
- Merck & Co Inc
- Daiichi Sankyo Co Ltd
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For